Assembly Biosciences reports FY23 EPS ($13.38) vs. ($23.08) last year

Reports FY23 collaboration revenue $7.16M vs. $0 last year. “Our progress in 2023 demonstrated our capacity to drive our expanded antiviral pipeline forward and our commitment to individuals suffering from life-impacting viral diseases. With our long-term partnership in place with Gilead and the addition of Dr. Anuj Gaggar to our management team as CMO, we are well-positioned to make critical progress clinically across multiple programs in 2024 and look forward to sharing preliminary data on 5366 and 4334 later this year,” said Jason Okazaki, CEO and president of Assembly Bio. Among anticipated milestones and events, the company listed: By mid-year 2024: ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor targeting recurrent genital herpes, is expected to enter a Phase 1a/1b study; ABI-4334, a next-generation, highly potent capsid assembly modulator, is anticipated to enter a Phase 1b study in individuals with chronic hepatitis B virus infection; By Q3 2024: Interim clinical data from the ABI-5366 Phase 1a study portion expected to be available. By the end of 2024: Interim clinical data from the ABI-4334 Phase 1b study expected to be available; The Phase 1b portion of the ABI-5366 study, in individuals with recurrent genital herpes, is anticipated to be underway. Two additional candidates are anticipated to enter the clinic: ABI-1179, a long-acting HSV helicase-primase inhibitor contributed by Gilead under the collaboration between Assembly Bio and Gilead; ABI-6250, a small molecule orally-bioavailable hepatitis delta virus entry inhibitor.